The most common grade ≥3 TEAEs (in >5% of patients) were decreased neutrophil count, anemia, increased alanine aminotransferase, decreased WBC count, decreased appetite, neutropenia, and pneumonia, which are generally consistent with the known safety profile for cemiplimab in combination with chemotherapy. This evidence concerns the gene GPT and susceptibility to pneumonia measurement.